Form 4: Aktis Oncology Director Sells Shares
Insider Transaction (Form 4)
Ken Herrmann, a Director of Aktis Oncology, Inc., sold 4,856 shares of common stock on July 20, 2026 for $24.56 per share.
Summary
- Option exercise/conversion: acquired 3,506 Common Stock at $0.08 ($280) on July 20, 2026; holds 3,506 after (Direct).
- Option exercise/conversion: acquired 1,350 Common Stock at $1.91 ($2,578) on July 20, 2026; holds 4,856 after (Direct).
- Open-market sale: disposed of 3,506 Common Stock at $24.56 ($86,115) on July 20, 2026; holds 1,350 after (Direct).
- Open-market sale: disposed of 1,350 Common Stock at $24.56 ($33,159) on July 20, 2026 (Direct).
- Option exercise/conversion: disposed of 3,506 Stock Option (Right to Buy) on July 20, 2026 (Direct).
- Option exercise/conversion: disposed of 1,350 Stock Option (Right to Buy) on July 20, 2026; holds 18,364 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $119,274 of stock on the open market.
Insider Transactions
Ken Herrmann — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-20 | Option exercise/conversion | Common Stock | 3,506 | $0 | $280 | 3,506 |
| 2026-07-20 | Option exercise/conversion | Common Stock | 1,350 | $2 | $2.6K | 4,856 |
| 2026-07-20 | Open-market sale | Common Stock | 3,506 | $25 | $86.1K | 1,350 |
| 2026-07-20 | Open-market sale | Common Stock | 1,350 | $25 | $33.2K | 0 |
| 2026-07-20 | Option exercise/conversion | Stock Option (Right to Buy) | 3,506 | — | — | 0 |
| 2026-07-20 | Option exercise/conversion | Stock Option (Right to Buy) | 1,350 | — | — | 18,364 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-20 | Option exercise/conversion (3,506 shares) |
| 2026-07-20 | Option exercise/conversion (1,350 shares) |
| 2026-07-20 | Open-market sale (3,506 shares) |
| 2026-07-20 | Open-market sale (1,350 shares) |
| 2026-07-20 | Option exercise/conversion (3,506 shares) |
| 2026-07-20 | Option exercise/conversion (1,350 shares) |
Keywords
insider transaction, Form 4, AKTS, Aktis Oncology, Inc., bearish, Ken Herrmann
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.